Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Q32 Bio Inc(QTTB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for QTTB
11/13/2026: QTTB (2-star) is currently NOT-A-BUY. Pass it for now.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. Its primary strengths lie in a targeted pipeline of biologic candidates that address key immune system regulators, alongside an experienced management team. The core investment story centers on the potential of bempikibart and ADX-914 to deliver improved outcomes in high-need patient populations. Key risks include the binary nature of clinical trials, substantial competitive pressure from established firms, and the ongoing need for capital. The stock is best suited for risk-tolerant investors who monitor clinical data catalysts and regulatory milestones in the biotechnology sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to the biotech sector but lacks current revenue growth. |
| Momentum investor | Mixed fit | Momentum may build around clinical data catalysts, but the stock is subject to high volatility. |
| Value investor | Weak fit | Valuation is difficult due to the absence of earnings and commercial-stage assets. |
| Dividend investor | Weak fit | The company is in an early growth phase and does not pay a dividend. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently high-risk, particularly for companies without commercial revenue. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks fluctuate significantly based on regulatory and trial-related news. |
| Valuation risk | High | Investors rely on long-term pipeline potential, making valuation subjective and sensitive to market sentiment. |
| Competition risk (immune-mediated disease landscape) | High | Established players have massive R&D budgets that can challenge Q32's novel therapies. |
| Business quality | Medium | The company has a focused science-driven approach, but lacks a diversified commercial portfolio. |
| Dividend income | Low / none | This is an early-stage growth company with no expectations for income. |
| Execution risk | High | Success depends entirely on the ability to conduct trials successfully and obtain regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 263.93M USD | Price to earnings Ratio 2.45 | 1Y Target Price 39.67 |
Price to earnings Ratio 2.45 | 1Y Target Price 39.67 | ||
Volume (30-day avg) 499.4K shares | Beta -0.11 | 52 Weeks Range 1.91 - 23.57 | Updated Date 11/13/2026 |
52 Weeks Range 1.91 - 23.57 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.6 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 693.46% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biotechnology Research & Development | Clinical and preclinical drug development for bempikibart and ADX-914. | The company currently burns cash to develop drugs and has no products generating sales yet. |
Valuation
Trailing PE 2.45 | Forward PE - | Enterprise Value -9.17M | Price to Sales(TTM) 4.91 |
Enterprise Value -9.17M | Price to Sales(TTM) 4.91 | ||
Enterprise Value to Revenue 2.98 | Enterprise Value to EBITDA 4.46 | Shares Outstanding 29.92M | Shares Floating 13.67M |
Shares Outstanding 29.92M | Shares Floating 13.67M | ||
Percent Insiders 2.07 | Percent Institutions 95.96 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.